Page 88 - Read Online

Qu et al. Hepatoma Res 2020;6:38 Hepatoma Research
DOI: 10.20517/2394-5079.2020.12

Review Open Access

Conventional type 1 dendritic cells in protective
antitumor immunity and its potential in

hepatocellular carcinoma

Chunfeng Qu, Kun Chen, Shao-Yan Cheng

State Key Lab of Molecular Oncology & Immunology Department, National Cancer Center/National Clinical Research Center
for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Correspondence to: Prof. Chunfeng Qu, State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research
Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan
South lane, Chaoyang District, Beijing 100021, China. E-mail: quchf@cicams.ac.cn

How to cite this article: Qu C, Chen K, Cheng SY. Conventional type 1 dendritic cells in protective antitumor immunity and its
potential in hepatocellular carcinoma. Hepatoma Res 2020;6:38. http://dx.doi.org/10.20517/2394-5079.2020.12

Received: 6 Feb 2020 First Decision: 18 Mar 2020 Revised: 27 Apr 2020 Accepted: 8 Jun 2020 Published: 10 Jul 2020

Academic Editor: Ying-Hong Shi Copy Editor: Cai-Hong Wang Production Editor: Jing Yu

Received: First Decision: Revised: Accepted: Published:
Abstract
Science Editor: Copy Editor: Production Editor: Jing Yu Immunotherapy is revolutionizing the clinical management of cancer patients by modulating T cells and natural
killer cells. Dendritic cells (DCs) have the capacity to orchestrate the expansion and function of these effector cells
both in lymphoid and non-lymphoid tissues of cancer patients. Distinct subtypes of DCs have various capacities to
prime and activate different T cell responses. Here, we review conventional type 1 dendritic cells (cDC1s) and their
crucial role in protective anti-tumor immunity. Targeting cDC1s as a cancer vaccine against the development of
hepatocellular carcinoma will be discussed.

Keywords: Conventional type 1 dendritic cells, antitumor immunity, hepatocellular carcinoma, cancer vaccine

INTRODUCTION
Immunotherapy is now widely considered as an important tool for the treatment of individuals with
cancer. Several effective immunotherapy approaches have been developed over the past decade, including
adoptive cell transfer (e.g., CAR-T therapy) and immune checkpoint blockade (e.g., anti-PD1/PDL1
[1,2]
antibodies) . In solid tumors including hepatocellular carcinoma (HCC), the tumor microenvironment
contains a large amount of stromal cells and immune cells, which shape cancer development and impact

© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.hrjournal.net